GE HealthCare Extends Partnership with RadNet’s DeepHealth to Scale AI Mammography Access Globally

GE HealthCare has expanded its partnership with DeepHealth, a subsidiary of RadNet, in order to innovate and commercialize advanced AI-powered mammography tools. The society of Breast Imaging Annual Symposium 2026 is one of the events with which the announcement was made. This is a huge step toward introducing advanced artificial intelligence into the usual workflows of mammography, enhancing their early detection and clinical outcomes.

Strengthening AI-Driven Breast Cancer Screening Capabilities

The broadened collaboration is based on a collaborative project that was carried out in 2024. This merged DeepHealth AI-enhanced screening capabilities with the Senographe Pristina mammography offered by GE HealthCare. The second stage brings in improved features with the DeepHealth Breast Suite. There is a cloud solution that makes the workflow easier by streamlining all processes involved in breast imaging and enhancing diagnostic accuracy.

The centerpiece of this partnership is incorporating cutting-edge AI software, such as ProFound Pro and Safeguard Review. These tools assist radiologists by automatically detecting lesions, measuring breast density, and indicating complex cases that could be subject to further examination. The solution allows the implementation of more efficient workflows without affecting clinical practices by integrating these capabilities into already existing imaging systems.

According to Jyoti Gupta, CEO of Womenopathy Health and X-ray technologies at GE HealthCare, we are enabling patients to have breast cancer spotted at an earlier age and with more certainty with the application of AI-based insights and innovative imaging technologies.

According to Precedence Research, the CAD Mammography Market size was calculated at USD 1.10 billion in 2025 and is predicted to increase from USD 1.20 billion in 2026 to approximately USD 2.70 billion by 2035, expanding at a CAGR of 9.40% from 2026 to 2035. The market growth is attributed to rising breast cancer screening volumes, increasing AI integration in imaging workflows, and growing demand for early and accurate diagnosis.

Industry Impact and Future Outlook

Early breast cancer detection is increasingly becoming crucial in the world as the incidence rates increase. The World Health Organization has listed breast cancer as one of the most prevalent cancers in the world, necessitating more screening measures. AI-enabled tools are being increasingly identified as a major facilitator in overcoming this difficulty, where there is the possibility to improve detection rates and decrease diagnostic variability. Furthermore, GE HealthCare is demonstrating a wider range of innovations at SBI 2026, further creating a strong presence in the market.